Published in Infect Immun on May 01, 1996
Pathogenesis of group A streptococcal infections. Clin Microbiol Rev (2000) 15.35
Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev (1999) 7.76
Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol (2011) 2.81
Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest (1996) 2.57
Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev (2014) 2.20
Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun (1997) 2.13
Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun (1998) 2.00
Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest (1998) 1.87
Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect Immun (1997) 1.68
Emergence of a New Highly Successful Acapsular Group A Streptococcus Clade of Genotype emm89 in the United Kingdom. MBio (2015) 1.54
atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol (2004) 1.52
Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proc Natl Acad Sci U S A (2008) 1.45
New protective antigen of group A streptococci. J Clin Invest (1999) 1.39
CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest (2000) 1.30
Acquisition of regulators of complement activation by Streptococcus pyogenes serotype M1. Infect Immun (2002) 1.24
Trading Capsule for Increased Cytotoxin Production: Contribution to Virulence of a Newly Emerged Clade of emm89 Streptococcus pyogenes. MBio (2015) 1.24
Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect Immun (1998) 1.20
Genome-wide identification of genes required for fitness of group A Streptococcus in human blood. Infect Immun (2013) 1.18
Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun (2000) 1.13
Impact of the SpeB protease on binding of the complement regulatory proteins factor H and factor H-like protein 1 by Streptococcus pyogenes. Infect Immun (2005) 1.04
First Streptococcus pyogenes signature-tagged mutagenesis screen identifies novel virulence determinants. Infect Immun (2009) 1.04
The hyaluronic acid capsule of Streptococcus uberis is not required for the development of infection and clinical mastitis. Infect Immun (2003) 1.03
Role of group A streptococcal virulence factors in adherence to keratinocytes. Infect Immun (2000) 1.03
Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin s operon in invasive M1T1 Group A Streptococcus. J Bacteriol (2006) 1.03
Production of stabilized virulence factor-negative variants by group A streptococci during stationary phase. Infect Immun (1998) 1.00
Streptococcus iniae capsule impairs phagocytic clearance and contributes to virulence in fish. J Bacteriol (2006) 1.00
Spa contributes to the virulence of type 18 group A streptococci. Infect Immun (2001) 0.97
Conversion of M serotype 24 of Streptococcus pyogenes to M serotypes 5 and 18: effect on resistance to phagocytosis and adhesion to host cells. Infect Immun (1997) 0.92
Streptococcus suis capsular polysaccharide inhibits phagocytosis through destabilization of lipid microdomains and prevents lactosylceramide-dependent recognition. Infect Immun (2011) 0.91
Mechanisms of group A Streptococcus resistance to reactive oxygen species. FEMS Microbiol Rev (2015) 0.89
Inhibition of dendritic cell maturation by group A Streptococcus. J Infect Dis (2009) 0.87
Clinical and molecular characteristics of invasive and noninvasive skin and soft tissue infections caused by group A Streptococcus. J Clin Microbiol (2011) 0.87
The fibrinogen-binding M1 protein reduces pharyngeal cell adherence and colonization phenotypes of M1T1 group A Streptococcus. J Biol Chem (2013) 0.86
Regulatory role of GSK-3 β on NF- κ B, nitric oxide, and TNF- α in group A streptococcal infection. Mediators Inflamm (2013) 0.83
Attenuated expression of the mga virulence regulon in an M serotype 50 mouse-virulent group A streptococcal strain. Infect Immun (1999) 0.83
Streptolysin O Rapidly Impairs Neutrophil Oxidative Burst and Antibacterial Responses to Group A Streptococcus. Front Immunol (2015) 0.83
A conserved UDP-glucose dehydrogenase encoded outside the hasABC operon contributes to capsule biogenesis in group A Streptococcus. J Bacteriol (2012) 0.82
Restoration of Mga function to a Streptococcus pyogenes strain (M Type 50) that is virulent in mice. Infect Immun (2001) 0.81
Inflammatory regulation of valvular remodeling: the good(?), the bad, and the ugly. Int J Inflam (2011) 0.81
Streptococcal pyrogenic exotoxin B causes mitochondria damage to polymorphonuclear cells preventing phagocytosis of group A streptococcus. Med Microbiol Immunol (2005) 0.81
Mutual exclusivity of hyaluronan and hyaluronidase in invasive group A Streptococcus. J Biol Chem (2014) 0.80
Engineering antiphagocytic biomimetic drug carriers. Ther Deliv (2013) 0.79
Conquering Neutrophils. PLoS Pathog (2016) 0.78
Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci. Eur J Clin Microbiol Infect Dis (2009) 0.78
The AgI/II family adhesin AspA is required for respiratory infection by Streptococcus pyogenes. PLoS One (2013) 0.76
Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection. Vaccine (2014) 0.76
Complement inhibition by Sarcoptes scabiei protects Streptococcus pyogenes - An in vitro study to unravel the molecular mechanisms behind the poorly understood predilection of S. pyogenes to infect mite-induced skin lesions. PLoS Negl Trop Dis (2017) 0.75
Interleukin-17A Contributes to the Control of Streptococcus pyogenes Colonization and Inflammation of the Female Genital Tract. Sci Rep (2016) 0.75
The Regulatory Small RNA MarS Supports Virulence of Streptococcus pyogenes. Sci Rep (2017) 0.75
A Red Blood Cell Membrane-Camouflaged Nanoparticle Counteracts Streptolysin O-Mediated Virulence Phenotypes of Invasive Group A Streptococcus. Front Pharmacol (2017) 0.75
Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A (1977) 14.75
Current knowledge of type-specific M antigens of group A streptococci. J Immunol (1962) 14.71
Studies of phagocytosis of group A streptococci by polymorphonuclear leucocytes in vitro. J Exp Med (1960) 12.03
Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med (1957) 10.14
Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev (1989) 7.80
Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface. Proc Natl Acad Sci U S A (1981) 5.56
Epithelial cell binding of group A streptococci by lipoteichoic acid on fimbriae denuded of M protein. J Exp Med (1976) 5.55
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Studies on the pathogenicity of group A streptococci. II. The antiphagocytic effects of the M protein and the capsular gel. J Exp Med (1959) 4.02
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A (1988) 3.82
Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen. J Exp Med (1977) 3.62
Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A (1991) 3.60
Size variation of the M protein in group A streptococci. J Exp Med (1985) 3.45
Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis (1992) 2.91
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Application of the polymerase chain reaction to study the M protein(-like) gene family in beta-hemolytic streptococci. Med Microbiol Immunol (1991) 2.44
Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol (1982) 2.27
Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest (1982) 2.19
Hyaluronate capsule prevents attachment of group A streptococci to mouse peritoneal macrophages. Infect Immun (1981) 2.03
Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun (1994) 1.92
Molecular evolution of streptococcal M protein: cloning and nucleotide sequence of the type 24 M protein gene and relation to other genes of Streptococcus pyogenes. J Bacteriol (1988) 1.86
Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci U S A (1994) 1.85
Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. J Exp Med (1983) 1.82
Biochemical and biological properties of the binding of human fibrinogen to M protein in group A streptococci. J Bacteriol (1985) 1.77
Dichotomy between opsonization and serum complement activation by encapsulated staphylococci. Infect Immun (1978) 1.56
Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol (1995) 1.48
Comparison of the leader sequences of four group A streptococcal M protein genes. Nucleic Acids Res (1988) 1.44
Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun (1995) 1.44
Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A Streptococci. II. Human plasma cofactor (s) enhancing opsonization of encapsulated organisms. J Exp Med (1963) 1.41
High-frequency S-layer protein variation in Campylobacter fetus revealed by sapA mutagenesis. Mol Microbiol (1994) 1.29
Role of fibrinogen in complement inhibition by streptococcal M protein. Infect Immun (1992) 1.17
Human fibrinogen specifically binds hyaluronic acid. J Biol Chem (1986) 1.17
Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol (1993) 1.14
M proteins of group G streptococci: mechanisms of resistance to phagocytosis. J Infect Dis (1995) 0.98
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol Microbiol (1998) 3.84
The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol (1998) 2.78
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest (1996) 2.57
Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest (1998) 2.47
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun (1997) 2.13
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Identification of cpsD, a gene essential for type III capsule expression in group B streptococci. Mol Microbiol (1993) 2.09
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest (1998) 1.87
Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature (2001) 1.76
Reduction of incorrect antibiotic dosing through a structured educational order form. Arch Intern Med (1988) 1.59
The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. Am J Med (1998) 1.54
Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1994) 1.53
Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection. Cell Microbiol (2000) 1.49
Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus. J Infect Dis (1981) 1.48
Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest (1992) 1.45
Flucytosine interference in creatinine assay. J Infect Dis (1990) 1.39
Aspergillus fumigatus arp1 modulates conidial pigmentation and complement deposition. Mol Microbiol (1997) 1.32
Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Mol Microbiol (1998) 1.30
Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis (1999) 1.30
CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest (2000) 1.30
Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1992) 1.27
Oxidative killing of Aspergillus fumigatus proceeds by parallel myeloperoxidase-dependent and -independent pathways. Infect Immun (1987) 1.26
Molecular analysis of the capsule gene region of group A Streptococcus: the hasAB genes are sufficient for capsule expression. J Bacteriol (1998) 1.26
Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus. J Biol Chem (2000) 1.21
An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem (1990) 1.18
Binding and germination of Aspergillus fumigatus conidia on cultured A549 pneumocytes. J Infect Dis (1997) 1.14
Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol Microbiol (2001) 1.10
Characterization of cpsF and its product CMP-N-acetylneuraminic acid synthetase, a group B streptococcal enzyme that can function in K1 capsular polysaccharide biosynthesis in Escherichia coli. Mol Microbiol (1996) 1.10
Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol (1985) 1.07
Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun (2001) 1.06
Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis (1986) 1.05
Group B streptococcal opacity variants. J Bacteriol (1992) 1.05
Phagocytic and fungicidal activity of monocytes from patients with acquired immunodeficiency syndrome. J Infect Dis (1985) 1.04
Two acute pediatric abdominal catastrophes from strangulated left paraduodenal hernias. Pediatr Emerg Care (1998) 1.02
Campylobacter jejuni strains from patients with Guillain-Barré syndrome. Emerg Infect Dis (1998) 1.02
Susceptibility of Helicobacter pylori to the bactericidal activity of human serum. Helicobacter (1996) 1.00
Hormones, receptors, and cyclic AMP: their role in target cell refractoriness. Curr Top Cell Regul (1980) 1.00
Differences between agonist and antagonist binding following beta-adrenergic receptor desensitization. J Biol Chem (1978) 0.99
Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci. Infect Immun (1993) 0.98
Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus. J Immunol (1999) 0.95
Fetal and maternal monitoring in spontaneous labors and in elective inductions. A comparative study. Am J Obstet Gynecol (1974) 0.94
C1q enhances the phagocytosis of Cryptococcus neoformans blastospores by human monocytes. J Immunol (1988) 0.93
Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J Infect Dis (1997) 0.91
Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) (1998) 0.90
Selective alteration in high affinity agonist binding: a mechanism of beta-adrenergic receptor desensitization. Mol Pharmacol (1979) 0.90
Cloning, sequence analysis and expression of the group A streptococcal guaB gene encoding inosine monophosphate dehydrogenase. Gene (1995) 0.89
Molecular analysis of two group B streptococcal virulence factors. Semin Perinatol (1990) 0.89
An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. Vox Sang (2009) 0.89
Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun (1994) 0.89
Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci. J Bacteriol (1994) 0.87
Visceral botryomycosis caused by Neisseria mucosa in a patient with chronic granulomatous disease. J Infect Dis (1985) 0.86
[Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme)]. Hospital (Rio J) (1966) 0.86
Anticryptococcal activity of NK cell-enriched peripheral blood lymphocytes from human immunodeficiency virus-infected subjects: responses to interleukin-2, interferon-gamma, and interleukin-12. J Infect Dis (1995) 0.86
An enzymatic method for 5-fluorocytosine. Clin Chem (1988) 0.83
Molecular size affects antigenicity of type III, group B Streptococcus capsular polysaccharide. Trans Assoc Am Physicians (1985) 0.83
Characterization of the capsular polysaccharide genes of group B streptococci. Dev Biol Stand (1995) 0.83
Acquired von Willebrand's disease in myelofibrosis and essential thrombocythemia. Haemophilia (2013) 0.83
Hyaluronic acid capsule modulates interactions of group A streptococci with human epidermal keratinocytes. Adv Exp Med Biol (1997) 0.80
Effect of hospitalwide change in clindamycin dosing schedule on clinical outcome. Rev Infect Dis (1989) 0.79
Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS (1995) 0.78
Cryptococcus neoformans myositis in a patient with AIDS. Clin Infect Dis (1995) 0.78
Glycolipid intermediates in biosynthesis of group B streptococcal capsular polysaccharide. Adv Exp Med Biol (1997) 0.77
Correct structure of repeating unit of group B Streptococcus type III capsular polysaccharide. J Infect Dis (1990) 0.77
Defining/measuring the value of clinical information. Clin Leadersh Manag Rev (2001) 0.77
Human granulocytic ehrlichiosis presenting as facial diplegia in a 42-year-old woman. Clin Infect Dis (2000) 0.76
Effects of methylmercury exposure during the second stage of rapid postnatal brain growth on negative geotaxis and on delta-aminolevulinate dehydratase of suckling rats. Braz J Med Biol Res (1993) 0.76
Measurement of human antibodies to type III group B Streptococcus. Infect Immun (1999) 0.76
Paracoccidioidomycosis case report: cure with amphotericin B and triple sulfa. J Med Vet Mycol (1986) 0.75
Mechanisms of host defence against fungal infection. J Med Vet Mycol (1992) 0.75
Identification of a gene similar to ABC transporters near the capsule synthesis region of the group A streptococcal chromosome. Dev Biol Stand (1995) 0.75
Role of complement and complement receptor C1qR in the antibody-independent killing of group B streptococcus. Adv Exp Med Biol (1997) 0.75
High-sensitivity dispersive Mach-Zehnder interferometer based on a dissimilar-doping dual-core fiber for sensing applications. Opt Lett (2014) 0.75
Regulation of hyaluronic acid capsule production by the has operon promoter in group A streptococci. Adv Exp Med Biol (1997) 0.75
Dominantly transmitted hematologic dysfunction clinically similar to Fanconi's anemia. Am J Hematol (1989) 0.75
Aspergillus and aspergillosis. J Med Vet Mycol (1992) 0.75
Rapid enzymatic method for measurement of serum flucytosine levels. J Antimicrob Chemother (1986) 0.75
Health transitions and complex systems. A challenge to prediction? Ann N Y Acad Sci (1994) 0.75
Membrane attack complex generation increases as a function of time in stored blood. Transfus Med (2014) 0.75
Cross-validation of modified fatness-specific bioelectrical impedance equations. Int J Sport Nutr (1999) 0.75
Binding of complement to trypomastigotes of a Brazil strain of Trypanosoma cruzi: evidence for heterogeneity within the strain. J Parasitol (1992) 0.75
Invasive Aspergillus infections complicating coronary artery bypass grafting. South Med J (1990) 0.75